Detail akcie 60 Degrees Ph Rg online

Business Summary: 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, 60 Degrees Pharmaceuticals Inc revenues increased from $420K to $1.1M. Net loss applicable to common stockholders increased 1% to $6.3M. Revenues reflect Research Revenues increase from $43K to $391K, Product Revenues net of Discounts and increase of 92% to $702K. Basic Earnings per Share excluding Extraordinary Items increased from -$95.79 to -$13.93.